InvestorsObserver
×
News Home

Does Alnylam Pharmaceuticals, Inc. (ALNY) Have What it Takes to be in Your Portfolio Friday?

Friday, May 20, 2022 02:10 PM | InvestorsObserver Analysts

Mentioned in this article

Does Alnylam Pharmaceuticals, Inc. (ALNY) Have What it Takes to be in Your Portfolio Friday?

Alnylam Pharmaceuticals, Inc. (ALNY) is near the top in its industry group according to InvestorsObserver. ALNY gets an overall rating of 59. That means it scores higher than 59 percent of stocks. Alnylam Pharmaceuticals, Inc. gets a 78 rank in the Biotechnology industry. Biotechnology is number 69 out of 148 industries.

Overall Score - 59
ALNY has an Overall Score of 59. Find out what this means to you and get the rest of the rankings on ALNY!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Alnylam Pharmaceuticals, Inc. Stock Today?

Alnylam Pharmaceuticals, Inc. (ALNY) stock is up 1.45% while the S&P 500 is down -1.72% as of 1:54 PM on Friday, May 20. ALNY has gained $1.88 from the previous closing price of $129.36 on volume of 449,349 shares. Over the past year the S&P 500 is lower by -7.83% while ALNY is down -6.32%. ALNY lost -$7.48 per share the over the last 12 months. Click Here to get the full Stock Report for Alnylam Pharmaceuticals, Inc. stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App